- Recursion Pharmaceuticals recently reported first-quarter 2026 results showing revenue of US$6.47 million and a net loss of US$117.5 million, while founder Chris Gibson decided not to seek re-election to the board after June 2026 but will continue as an advisor.
- At the same time, investors are closely watching the company’s advancing AI-enabled pipeline, including REC-4881 and REC-1245, amid ongoing FDA engagement on potential registrational pathways.
- We’ll now examine how Recursion’s FDA discussions around REC-4881 and other AI-derived candidates may reshape its longer-term investment narrative.
This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
Recursion Pharmaceuticals Investment Narrative Recap
To own Recursion, you have to believe its AI-driven platform can eventually turn a broad early-stage pipeline into approved drugs, despite continued heavy losses and reliance on partner revenue. Right now, the key near-term catalyst is the FDA feedback on a registrational path for REC-4881 in familial adenomatous polyposis, while the most immediate risk is ongoing cash burn and the possibility of future dilution; the latest Q1 results and board changes do not materially change that trade-off.
Among recent developments, the progress around REC-4881 stands out as most relevant. Positive Phase 2 data in FAP and active discussions with the FDA on study design give this program clear visibility as the next major clinical inflection point. Any clarity on whether the upcoming study can support registration will be watched closely, especially as Recursion also advances other AI-derived assets like REC-1245 and REC-4539 through earlier stages of development.
Yet beneath the excitement around REC-4881, investors should be aware that ongoing cash burn and a limited runway through 2027 could still...
Read the full narrative on Recursion Pharmaceuticals (it's free!)
Recursion Pharmaceuticals’ narrative projects $220.9 million revenue and $35.5 million earnings by 2028.
Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 115% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were already assuming only about US$102.1 million of revenue and US$16.6 million of earnings by 2028, which is far more cautious than the consensus. When you compare that pessimism with the current focus on REC-4881 and cash runway risks, it highlights how widely views can differ and why you may want to weigh several perspectives before deciding how this latest FDA and earnings news might reshape the story.
Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth over 3x more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 37 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com